Search alternatives:
points decrease » point decrease (Expand Search), point increase (Expand Search)
teer decrease » mean decrease (Expand Search), greater decrease (Expand Search)
nn decrease » _ decrease (Expand Search), mean decrease (Expand Search), gy decreased (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
50 points » 5 points (Expand Search), 5 point (Expand Search), _ points (Expand Search)
points decrease » point decrease (Expand Search), point increase (Expand Search)
teer decrease » mean decrease (Expand Search), greater decrease (Expand Search)
nn decrease » _ decrease (Expand Search), mean decrease (Expand Search), gy decreased (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
50 points » 5 points (Expand Search), 5 point (Expand Search), _ points (Expand Search)
-
1501
Proposed model for vRNP assembly on Rab11a+ vesicles.
Published 2021“…In the absence of Rab11a, vRNPs are scattered in the cytoplasm, decreasing the likelihood of association between the eight individual RNP segments, and ultimately resulting in the production of defective particles with misassembled genomes. …”
-
1502
A picture of service-bed compartment of the gamma spectrometry vehicle used in the experiment.
Published 2022Subjects: -
1503
Visualisation of relative alignment of the count-rate function and the acquisition time intervals.
Published 2022Subjects: -
1504
-
1505
-
1506
-
1507
-
1508
-
1509
Illustration of the path of the vehicle and the positions of the radioactive sources.
Published 2022Subjects: -
1510
-
1511
-
1512
-
1513
-
1514
-
1515
-
1516
-
1517
-
1518
The effects of pretreatment with fingolimod-phosphate on BMECs in the presence of MS sera.
Published 2015“…Pretreatment with fingolimod-phosphate resulted in an increase in the claudin-5 protein levels (B) and TEER values (G) and a decrease in the VCAM-1 protein levels (F) in the BMECs, which were upregulated after exposure to the sera from all MS patients, including the RRMS-R, RRMS-S and SPMS patients, compared to that observed in the cells not pretreated with fingolimod-phosphate.…”
-
1519
-
1520